CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround

Stock News04-01

CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement follows the company's release of its annual results. Full-year revenue reached RMB 1.059 billion, a year-on-year increase of 28.43%. Profit attributable to owners of the company was RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, the company announced a shareholder dividend return plan for the next three years, emphasizing a priority on cash dividends. According to the announcement, the performance growth during the reporting period was primarily driven by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company has continued to implement its development strategy focused on innovation and commercialization, advanced cost reduction and efficiency improvement measures, and optimized production and sales coordination, leading to ongoing enhancements in operational efficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164679653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164679653","market":"fut","top_or_hot":-1,"title":"CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround","media":"Stock News","content":"<p>CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement follows the company's release of its annual results. Full-year revenue reached RMB 1.059 billion, a year-on-year increase of 28.43%. Profit attributable to owners of the company was RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, the company announced a shareholder dividend return plan for the next three years, emphasizing a priority on cash dividends. According to the announcement, the performance growth during the reporting period was primarily driven by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company has continued to implement its development strategy focused on innovation and commercialization, advanced cost reduction and efficiency improvement measures, and optimized production and sales coordination, leading to ongoing enhancements in operational efficiency.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement follows the company's release of its annual results. Full-year revenue reached RMB 1.059 billion, a year-on-year increase of 28.43%. Profit attributable to owners of the company was RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, the company announced a shareholder dividend return plan for the next three years, emphasizing a priority on cash dividends. According to the announcement, the performance growth during the reporting period was primarily driven by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company has continued to implement its development strategy focused on innovation and commercialization, advanced cost reduction and efficiency improvement measures, and optimized production and sales coordination, leading to ongoing enhancements in operational efficiency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1164679653","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164679653","pubTimestamp":1775016017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","BK4585":"ETF&股票定投概念","BK4588":"碎股","06185":"康希诺生物","BK1574":"生物医药B类股","BK1191":"制药","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","BK1515":"抗疫概念"},"translate_title":"脑膜炎球菌疫苗收入增长和年度利润扭亏为盈，康希诺生物股价午盘前飙升近10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"VXUS":1,"06185":1},"content_text":"CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement follows the company's release of its annual results. Full-year revenue reached RMB 1.059 billion, a year-on-year increase of 28.43%. Profit attributable to owners of the company was RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, the company announced a shareholder dividend return plan for the next three years, emphasizing a priority on cash dividends. According to the announcement, the performance growth during the reporting period was primarily driven by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company has continued to implement its development strategy focused on innovation and commercialization, advanced cost reduction and efficiency improvement measures, and optimized production and sales coordination, leading to ongoing enhancements in operational efficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164679653","isCrawlerRequest":true}